We want to give a very warm welcome as a new EIT Health Spain partner to Genesis Biomed, a company specialized in providing consulting services to spin-off and start-up companies, entrepreneurs and research centres. 🗞️ Read the new at goo.gl/4FjwWC

LK-01 Granted Orphan Drug Designation by the U.S. FDA for Acute Myeloid Leukemia leukosbiotech.com/news-1/2018/6/…

Leucemia, no lo olvides, vamos a por ti. Vamos a ponerte una fecha final para que todos los pacientes te sobrevivan. Necesitamos ser más contra ti. ¿Nos echas una mano? fcarreras.org/donaahora #PonleFecha

New article by Dr. Risueño's Lab and Leukos Biotech on the role of HTRs in MDS and CMML. leukosbiotech.com/news-1/2018/9/…

A New Biology for a New Century mmbr.asm.org/content/68/2/1…

Ruth Risueño Leukos Biotech és un dels casos d'èxit de #techtransfer a la #BioRegioCatalunya, avui ens ho explica a la presentació de l'#InformeBiocat

We are very happy to welcome our new Lab Manager: Lise Clément-Demange. leukosbiotech.com/team/

Regulatory Science to 2025 – launch of six-month public consultation | European Medicines Agency europa.eu/!Ub93NT

We are very proud to share with such great companies this space at the Institut de Recerca contra la Leucèmia Josep Carreras.

Meet the CEO of Minoryx, the Spanish Biotech Fighting Rare Disease labiotech.eu/interview-mino…

Save the date. Barcelona Peptide Therapeutics Symposium 2017, 20th September.

Bé, bé, bé. L'equip Spherium Biomed comença a preparar la barbacoa! #CataloniaBioBBQ Specipig

Leukos Biotech is certified as Innovative SME leukosbiotech.com/news-1/2017/7/…

⌛️🔜 #JornadaGENESISBiomed2017 en Parc Científic de Barcelona. Hablaremos de tendencias en emprendimiento #biofarma con Caixa Capital Risc, Peptomyc, AptaTargets y Leukos Biotech ow.ly/m1Y330fDeVn

Great news! Did you know that Leukos Biotech has developed a similar test for Acute Myeloid Leukaemia? x.com/NatureNews/sta…

We are very happy and proud! Our CSO, Dr. Ruth M. Risueño, received an accessit prize from the REAL ACADEMIA NACIONAL DE FARMACIA Real Academia Nacional de Farmacia.

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing in second half 2018 in Europe and later in the U.S.

We are hiring! leukosbiotech.com/news-1/2018/2/…